Blockage of Intermediate-conductance Ca2+-activated K+ Channels Inhibit Human Pancreatic Cancer Cell Growth in Vitro
Overview
Pharmacology
Affiliations
Ion channels are important in controlling cell cycle progression and proliferation in a variety of cell types. Using the whole-cell recording mode of the patch-clamp technique, functional ion channels were electrophysiologically characterized in PANC-1 (K-ras G12D (+/-), p53 R273C, Deltap16), BxPC-3 (smad4-, p53 Y220C, Deltap16), and MiaPaCa-2 [transforming growth factor-beta receptor type II defect, K-ras G12C(-/-), p53 R248W, Deltap16] human pancreatic cancer cell lines. In BxPC-3 and the MiaPaCa-2 cells, we could identify approximately 600 or approximately 1200 functional Ca2+-activated K+ channels (IK) per cell, respectively, whereas PANC-1 cells expressed approximately 200 functional IK channels per cell. These channels were observed by using pipette solutions buffering [Ca2+]i to 1 microM. The channels were voltage-independent, blocked by charybdotoxin, clotrimazole, 1-[(2-chlorophenyl) diphenylmethyl]-1H-pyrazole (TRAM-34), and blocked by Ba2+ in a voltage-dependent manner. In the presence of 10 microM clotrimazole or TRAM-34, proliferation of the BxPC-3 as well as the MiaPaCa-2 cells was completely stopped. In contrast, proliferation of PANC-1 cells was hardly affected by clotrimazole or TRAM-34. Proliferation in all three cell lines could be inhibited in the presence of the Ca2+ channel antagonists verapamil, diltiazem, and nifedipine. By quantitative RT-PCR, we could show that MiaPaCa-2 cells exhibit a 2.8-fold and BxPC3 cells a more than 8-fold elevated level of IK mRNA level compared with PANC-1 cells. Interestingly, in primary pancreatic tumors we found a tremendous up-regulation of IK mRNA. In eight of nine (or 89%) primary pancreatic tumor tissues, we found a 6- to 66-fold increase in IK mRNA. Our findings suggest that a certain amount of functional IK channels is crucial for the proliferation of some pancreatic cancer types. The blockade of IK channels may ultimately prove useful as a therapeutic option for some patients with ductal adenocarcinoma of the pancreas with an up-regulated IK channel expression.
Zuccolini P, Barbieri R, Sbrana F, Picco C, Gavazzo P, Pusch M Int J Mol Sci. 2023; 24(22).
PMID: 38003471 PMC: 10671816. DOI: 10.3390/ijms242216285.
Okada Y, Numata T, Sabirov R, Kashio M, Merzlyak P, Sato-Numata K Front Cell Dev Biol. 2023; 11:1246955.
PMID: 37842082 PMC: 10576435. DOI: 10.3389/fcell.2023.1246955.
Mlayah-Bellalouna S, Aissaoui-Zid D, Chantome A, Jebali J, Souid S, Ayedi E Front Pharmacol. 2023; 14:1203247.
PMID: 37426811 PMC: 10326281. DOI: 10.3389/fphar.2023.1203247.
Repurposing of Chronically Used Drugs in Cancer Therapy: A Chance to Grasp.
Hijazi M, Gessner A, El-Najjar N Cancers (Basel). 2023; 15(12).
PMID: 37370809 PMC: 10296024. DOI: 10.3390/cancers15123199.
Song Y, Deng Z, Sun H, Zhao Y, Zhao R, Cheng J J Transl Med. 2023; 21(1):390.
PMID: 37328854 PMC: 10273655. DOI: 10.1186/s12967-023-04260-x.